Multiple Myeloma | Clinical

April 15, 2021

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

April 14, 2021

Investigators reported an objective response rate of 73% for the anti–B-cell maturation antigen teclistamab in patients with relapsed/ refractory multiple myeloma, according to results from an ongoing study.

April 14, 2021

Adriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.

April 14, 2021

An expert in multiple myeloma shares her perspective on the significance of recent single-agent approvals for patients with triple-class refractory multiple myeloma and highlights promising combination regimens under investigation.

April 14, 2021

Dr Adrianna Rossi reviews considerations for treatment selection in the triple-class refractory setting in patients with multiple myeloma.

April 14, 2021

Adriana Rossi, MD, describes key clinical trials and their implications for the management of triple-class refractory multiple myeloma.

April 14, 2021

Dr Adriana Rossi reviews the therapeutic options for patients with triple-class refractory multiple myeloma in terms of mechanism of action and safety profile.

April 14, 2021

An expert in multiple myeloma provides insight on the treatment challenges for patients with triple-class refractory disease, particularly after fourth or later lines.

April 14, 2021

Adriana Rossi, MD, presents the case of a 75-year-old woman with triple-class refractory multiple myeloma.

April 14, 2021

Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.